Abstract
Breast cancer (BC) is one of the most common tumors to involve the leptomeninges. We aimed to characterize clinical features and outcomes of patients with LMD based on BC subtypes. We retrospectively reviewed records of 233 patients diagnosed with LMD from BC between 1997 and 2012. Survival was estimated by the Kaplan–Meier method and significant differences in survival were determined by Cox proportional hazards or log-rank tests. Of 190 patients with BC subtype available, 67 (35 %) had hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative BC, 56 (29 %) had HER2+BC, and 67 (35 %) had triple-negative BC (TNBC). Median age at LMD diagnosis was 50 years. Median overall survival (OS) from LMD diagnosis was 4.4 months for HER2+BC (95 % CI 2.8, 6.9), 3.7 months (95 % CI 2.4, 6.0) for HR+/HER2−BC, and 2.2 months (95 % CI 1.5, 3.0) for TNBC (p = 0.0002). Older age was associated with worse outcome (p < 0.0001). Patients with HER2+BC and LMD were more likely to receive systemic therapy (ST) (p = 0.001). Use of intrathecal therapy (IT) (52 %) was similar (p = 0.35). Both IT (p < 0.0001) and ST (p < 0.0001) administration were associated with improved OS. After adjusting for age, IT, extracranial disease, and ST, patients with HER2+BC had better OS compared with HR+/HER2−BC (HR 1.72; 95 %CI 1.07–2.76) and TNBC (HR 3.30; 95 %CI 1.98–5.52). LMD carries a dismal prognosis. Modest survival differences by tumor subtype were seen. Patients with HER2+BC had the best outcome. There is an urgent need to develop effective treatment strategies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25(2):103–119. doi:10.1053/ctrv.1999.0119
Aparicio A, Chamberlain MC (2002) Neoplastic meningitis. Curr Neurol Neurosci Rep 2(3):225–235
Jaeckle KA (2006) Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol 33(3):312–323. doi:10.1053/j.seminoncol.2006.04.016
Armstrong TS, Gilbert MR (2004) The treatment of neoplastic meningitis. Expert Opin Pharmacother 5(9):1929–1935. doi:10.1517/14656566.5.9.1929
Hoffmann AL, Buhk JH, Strik H (2009) Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. Anticancer Res 29(12):5191–5195
Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, Hart AA, Benraadt J, Vecht ChJ (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40(18):2726–2733. doi:10.1016/j.ejca.2004.08.012
Rudnicka H, Niwinska A, Murawska M (2007) Breast cancer leptomeningeal metastasis–the role of multimodality treatment. J Neurooncol 84(1):57–62. doi:10.1007/s11060-007-9340-4
Lin NU (2010) Concordance of HER2 in primary tumor and leptomeningeal metastases: now what? Breast Cancer Res Treat 123(1):129–131. doi:10.1007/s10549-009-0720-7
Meriggi F, Zaniboni A (2011) Newer avenues for the treatment of leptomeningeal carcinomatosis. Cent Nerv Syst Agents Med Chem 11(1):38–44
Le Rhun E, Taillibert S, Zairi F, Devos P, Pierret MF, Dubois F, Assaker R, Buisset E, Bonneterre J, Baranzelli MC (2011) Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study. J Neurooncol 105(2):309–315. doi:10.1007/s11060-011-0592-7
Lee S, Ahn HK, Park YH, do Nam H, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH (2011) Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat 129(3):809–817. doi:10.1007/s10549-011-1682-0
Torrejon D, Oliveira M, Cortes J, Sanchez-Olle G, Gomez P, Bellet M, Saura C, Peg V, Rovira A, Di Cosimo S (2013) Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast 22(1):19–23. doi:10.1016/j.breast.2012.10.009
Jang G, Lee SS, Ahn JH, Jung KH, Lee H, Gong G, Kim HH, Ahn SD, Son BH, Ahn SH, Kim SB (2011) Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. Breast Cancer Res Treat 128(1):171–177. doi:10.1007/s10549-011-1526-y
Lim E, Lin NU (2012) New insights and emerging therapies for breast cancer brain metastases. Oncology 26 (7):652-659, 663
Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW (2008) Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112(11):2359–2367. doi:10.1002/cncr.23468
Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR (1982) Treatment for meningeal carcinomatosis in breast cancer. Cancer 50(2):219–222
Conflict of interest
Dr. Smith reports grants from Varian Medical systems; outside the submitted work. Dr. Esteva reports fees from Genentech, personal fees from Novartis; outside the submitted work. Otherwise there are no financial disclosures, conflicts of interest, or funding sources for the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abouharb, S., Ensor, J., Loghin, M.E. et al. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat 146, 477–486 (2014). https://doi.org/10.1007/s10549-014-3054-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-014-3054-z